Cevec Pharmaceuticals (Cevec) and Inno Biologics have entered into a strategic license agreement. The license enables Inno Biologics to offer the full potential of production of their diagnostic and preclinical grade material in highest quality with authentic human glycosylation patterns using the proprietary Cap expression system.
Cap technology is the stable producing human cell line from Cevec. The non-tumor origin cells have highest expression rates of human proteins grow in serum-free suspension culture and post-translational modifications are human-like.
Rainer Lichtenberger, CEO of Cevec, said: “Because post-translational modifications play a significant role for the bioactivity of recombinant proteins it is very important to produce proteins with human-like glycosylation and sialylation.”
Rolf Werner, senior vice president of the corporate division biopharmaceuticals at Boehringer Ingelheim, said: “This agreement between our strategic manufacturing partner Inno Biologics and the innovation partner Cevec extends the technical capability represented in our Production Alliance Network for contract manufacturing of biopharmaceuticals into human cell line technology for manufacturing of highly glycosylated therapeutical proteins.”